Lupin Limited has announced that it has completed the acquisition of European speciality pharmaceutical company, VISUfarma, from GHO Capital Partners LLP (GHO).
In a statement, the company said that the acquisition symbolises a "significant milestone" in its strategy to expand its speciality care portfolio and strengthen its presence in Europe.
The acquisition of VISUfarma has greatly expanded Lupin's ophthalmology portfolio to more than 60 branded products, spanning dry eye, glaucoma, eyelid hygiene, blepharitis, retinal health and speciality nutraceuticals.
VISUfarma brings a strong commercial footprint in key European markets and a highly experienced team with deep ophthalmology expertise, trusted relationships and strong local market insight. The purchase enhances Lupin's ability to address the growing global demand for innovative eye care solutions, driven by an ageing population and the burden of diabetes-related eye complications.
Vinita Gupta, CEO, Lupin, said: "The VISUfarma acquisition marks a very exciting milestone for Lupin, adding a differentiated portfolio of more than 60 innovative eye health products supported by an established commercial infrastructure."
Beyond being immediately accretive, this strategic acquisition will also expand our presence across Europe and accelerate the build-out of our speciality franchise.
Paolo Cioccetti, CEO Italy, VISUfarma, added: "We are thrilled to embark on this next chapter with Lupin."
Their global expertise, vision and commitment to ophthalmology make them the ideal partner to take VISUfarma to the next level.
"Together, we are confident that we can make a significant impact in advancing eye care across Europe and beyond."